K-Lab Therapeutics is developing novel immunotherapies that target myeloid-derived suppressor cells (MDSC) and tumor cells to treat primary and metastatic cancers. With our unique approach, we identify novel molecular targets and develop effective drugs that can attenuate tumor-associated immune suppression, reduce cancer-related inflammation and trigger an anti-tumor immune response. Our current focus is building and validating a unique pipeline of first-in-class immunotherapies for cancer treatment.